Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 68071-3779

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-3779). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3779 3)

This text is a medication label for Duloxetine 30mg capsules. It includes information such as the National Drug Code (NDC), lot number, expiration date, and active ingredient. Additionally, it mentions the manufacturer's label, side effects, and instructions to contact a doctor for medical advice. The label also provides a warning to keep the medication out of reach of children and store it at a controlled temperature.*

FDA Label Image

Figure6 (Image 10)

This text presents the dosages of Duloretine (120 mg, 60 mg, and 20 mg) given once daily, along with a placebo for comparison. It also includes a table showing the percentage of patients improved and the percent improvement in pain from the baseline. This data likely comes from a study or clinical trial evaluating the effectiveness of Duloretine for pain management.*

FDA Label Image

Figure 7 (Image 11)

Percentage of Patients Improved through the use of Duloretine Delayed-Release 60mg Once Daily (b) compared to Placebo. The graph shows the percent improvement in pain from baseline, ranging from 0 to 100.*

FDA Label Image

Figure8 (Image 12)

This information provides data on the percentage of patients who experienced an improvement in pain with placebo versus Duloxetine Delayed-Release at 60 mg and 120 mg once daily. The chart illustrates the percentage of improvement in pain from baseline using a BOCF (Baseline Observation Carried Forward) method.*

FDA Label Image

Figure9 (Image 13)

This text shows data on the percentage of patients that improved with a placebo compared to Duloxetine Delayed-Release at a dosage of 60 mg taken once daily. It includes the percent improvement in pain from baseline as measured by BOCF. The values show how the patients responded over a range of improvement levels.*

FDA Label Image

Figure10 (Image 14)

This text provides information on the percentage of patients' improvement in pain based on different treatments. The data lists the improvement percentages of patients who received a placebo and those who were treated with Duloxetine Delayed-Release at doses of 60/120 mg once daily. The percentage values for the improvement in pain from baseline are also provided.*

FDA Label Image

Pdp (Image 16)

FDA Label Image

1 (Image 4)

FDA Label Image

Figure1 (Image 5)

This data represents the proportion of patients experiencing a relapse on Placebo versus Duloxetine Delayed-Release Capsules over a certain time period. The information is visualized in a graph showing time from randomization to relapse in days using the Kaplan-Meier estimator method. The x-axis ranges from 0 to 250 days, indicating the observation period for relapse occurrence.*

FDA Label Image

Figure2 (Image 6)

The text provides information on the proportion of patients with relapse over time for both the placebo and duloxetine delayed-release capsules treatments. The data is presented graphically, showing the time from randomization to relapse in days using the Kaplan-Meier estimator method. This information can be used to analyze the effectiveness of the treatments in preventing relapse in patients.*

FDA Label Image

Figure3 (Image 7)

This text provides information on the percentage of patients improved with different doses of Duloxetine and a placebo in relation to the percent improvement in pain from baseline. The percentages are associated with different doses of Duloxetine (80mg, 60mg, and 20mg) as well as placebo, allowing for comparison of effectiveness in pain relief.*

FDA Label Image

Figure4 (Image 8)

This text provides information about the percentage of patients improved with different treatment options for pain management, including Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and Placebo. It shows the percent improvement in pain from baseline for each treatment regimen.*

FDA Label Image

Figure5 (Image 9)

Percentage of Patients Improved with Duloxetine 60 mg Twice Daily, Duloxetine 60 mg Once Daily, and Placebo. The efficacy of each treatment is being evaluated based on the percent improvement in pain from baseline measurements.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.